COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,199 Articles (22,713 medRxiv, 8,486 bioRxiv)

Most recent first Previous |  Page 2124: Articles 21231-21240  | Next

Clinical evaluation of a fully automated, lab developed multiplex RT-PCR assay integrating dual-target SARS-CoV-2 and Influenza-A/B detection on a high-throughput platform
Nörz, D., Hoffmann, A., Aepfelbacher, M., Pfefferle, S., Lütgehetmann, M.
10.1101/2020.10.25.20215285 — Posted: 2020-10-27
Clinical Outcome of Asymptomatic COVID-19 Infection Among a Large Nationwide Cohort of 5,621 Hospitalized Patients in Korea
Park, H. C., Kim, D. H., Cho, A., Kim, J., Yun, K.-s., Kim, J., Lee, Y.-K.
10.1101/2020.10.25.20218982 — Posted: 2020-10-27
Rapid Development of a De Novo Convalescent Plasma Program in Response to a Global Pandemic: A Large Southeastern U.S. Blood Center's Experience
Reik, R., Gammon, R., Carol, N., Smith, J., Grable, M., Forbes, S., Wu, Y., Reed, L., Rogers, M., Prichard, A., Paul, S., Scholl, G.
10.1101/2020.10.23.20217901 — Posted: 2020-10-27
MEGA: Machine Learning-Enhanced Graph Analytics for COVID-19 Infodemic Control
Hang, C. N., Yu, P.-D., Ling, L., Tan, C. W.
10.1101/2020.10.24.20215061 — Posted: 2020-10-27
Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production and supply model
Russell, W. A., Grebe, E., Custer, B.
10.1101/2020.10.25.20219170 — Posted: 2020-10-27
Reducing Covid-19 risk in schools: a qualitative examination of staff and family views and concerns
Lorenc, A., Kesten, J. M., Kidger, J., Langford, R., Horwood, J.
10.1101/2020.10.25.20216937 — Posted: 2020-10-27
COVID -19: could green tea catechins reduce the risks?
Storozhuk, M.
10.1101/2020.10.23.20218479 — Posted: 2020-10-27 Discussion: Onsite
Establishment & lineage dynamics of the SARS-CoV-2 epidemic in the UK
du Plessis, L., McCrone, J. T., Zarebski, A. E., Hill, V., Ruis, C., Gutierrez, B., Raghwani, J., Ashworth, J., Colquhoun, R., Connor, T. R., Faria, N. R., Jackson, B., Loman, N. J., O'Toole, A., Nicholls, S. M., Parag, K. V., Scher, E., Vasylyeva, T. I., Volz, E. M., Watts, A., Bogoch, I. I., Khan, K., COG-UK consortium, , Aanensen, D., Kraemer, M. U. G., Rambaut, A., Pybus, O.
10.1101/2020.10.23.20218446 — Posted: 2020-10-27
Preliminary Estimates of Years of Life Lost (YLL) Due to COVID-19 in India
Indrayan, A., Mishra, A.
10.1101/2020.10.24.20218693 — Posted: 2020-10-27 Discussion: Onsite
Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in the Staff of a Public School System in the Midwestern United States
Lopez, L., Weber, G., Nguyen, T., Kleimola, K., Bereda, M., Liu, Y., Accorsi, E. K., Skates, S. J., Santa Maria, J. P., Smith, K. R., Kalinich, M.
10.1101/2020.10.23.20218651 — Posted: 2020-10-27 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).